Is this medical device maker built for scale?
Edwards Lifesciences is a medical technology company focused on devices used in patient care. It sells products used in clinical settings, with its business organized around delivering specialized, procedure-
Are profits translating into real cash flow?
FundamentalsFor 2025, reported in USD, revenue reached about USD 6.07 billion, alongside net income of roughly USD 1.06 billion. Margins remained elevated on a gross basis at 77.87% (TTM), while operating margin was 16.04% and net profit margin 17.39% (TTM). Revenue grew 11.5% year over year in the latest annual period.
The cash profile shows about USD 2.94 billion of cash against USD 598 million of total debt. With depreciation and amortization of USD 156.6 million and capital spending of USD 260.2 million, the EBIT-based cash flow proxy was negative USD 47.9 million, highlighting limited conversion of operating profit into cash after reinvestment. ROE over the trailing period was 10.42%.
Is the market overpaying for efficiency?
DCF / MultiplesAt USD 77.17, the share price stands well above the DCF-implied fair value range, even under the stronger scenario. The headline multiples reinforce that contrast, with a trailing P/E of 40.86 and EV/EBITDA of 33.14 accompanying that higher market price.
Valuation Depends on Cash Conversion
TakeawayThe price assumes returns on capital will look better than they do today. That can work if operating profit translates into real cash. It also needs reinvestment to stay controlled. If cash conversion stays weak, the valuation gap becomes hard to defend.